Dosimetric comparison of MRI-based HDR brachytherapy and stereotactic radiotherapy in patients with advanced cervical cancer: A virtual brachytherapy study  by Otahal, Bretislav et al.
OD
b
p
b
B
J
A
a
b
c
a
A
R
R
6
A
K
B
C
C
D
S
T
h
1reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 399–404
Available  online  at  www.sciencedirect.com
ScienceDirect
jou rn al hom ep age: ht tp : / /www.e lsev ier .com/ locate / rpor
riginal research article
osimetric  comparison  of  MRI-based  HDR
rachytherapy and  stereotactic  radiotherapy  in
atients with  advanced  cervical  cancer:  A virtual
rachytherapy study
retislav Otahala,∗, Martin Dolezelb, Jakub Cveka, Ondrej Simetkac,
aroslav Klat c, Lukas Knybela, Lukas Molendaa, Eva Skacelikovaa,
les  Hlavkab, David Feltl a
Department of Oncology, University Hospital Ostrava, Ostrava, Czech Republic
Oncology Centre, Multiscan & Pardubice Regional Hospital, Pardubice, Czech Republic
Department of Gynecology, University Hospital Ostrava, Ostrava, Czech Republic
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 11 June 2013
eceived in revised form
 January 2014
ccepted 5 April 2014
eywords:
rachytherapy
ervix carcinoma
yberKnife
osimetric study
tereotactic radiotherapy
a  b  s  t  r  a  c  t
Aim: To evaluate the treatment plans of 3D image-guided brachytherapy (BT) and stereotactic
robotic radiotherapy with online image guidance – CyberKnife (CK) in patients with locally
advanced cervix cancer.
Methods and materials: Ten pairs of plans for patients with locally advanced inoperable cervi-
cal  cancer were created using MR based 3D brachytherapy and stereotaxis CK. The dose that
covers 98% of the target volume (HR CTV D98) was taken as a reference and other parameters
were compared.
Results: Of the ten studied cases, the dose from D100 GTV was comparable for both devices,
on  average, the BT GTV D90 was 10–20% higher than for CK. The HR CTV D90 was  higher
for CK with an average difference of 10–20%, but only ﬁfteen percent of HR CTV (the periph-
eral  part) received a higher dose from CK, while 85% of the target volume received higher
doses from BT. We  found a signiﬁcant organ-sparing effect of CK compared to brachytherapy
(20–30% lower doses in 0.1 cm3, 1 cm3, and 2 cm3).
Conclusion: BT remains to be the best method for dose escalation. Due to the signiﬁcantorgan-sparing effect of CK, patients that are not candidates for BT could beneﬁt from stereo-taxis more than from clas
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1.  Background
Brachytherapy (BT) is an integral component of multimodality
treatment for advanced inoperable cervical cancer.1,2 The abil-
ity to deliver a very high target dose with a sharp dose gradient
is essential for obtaining excellent treatment results. MRI-
navigated BT further increases the therapeutic index due to
the precise irradiation of target volume (TV) and better organ
sparing.3–5
In cervical cancer treatment, external beam radiotherapy
(EBRT) is used to irradiate the whole pelvis. Compared to BT,
external boost is less effective and more  toxic.6 However, in
recent years, advances in EBRT have allowed radiation onco-
logists to deliver a highly conformal dose to the target, and
advances in image  guidance enable the reduction of set-up
margins.
It is difﬁcult to directly compare BT and EBRT, mainly
because of the different dose-volume parameters used for
each method. In comparing different radiotherapy plans, it
is crucial to establish a reference parameter. The GEC-ESTRO
Working Group recommends D90 as the most important
parameter for high-risk clinical target volume (HR CTV),4 but
D98 seems to be much better indicator for local tumor control7;
systematic low-dose regions leading to local recurrence could
be detected even when D90 for HR CTV ≥ 87 Gy was applied.
Modern EBRT planning systems (mostly for stereotactic RT) are
capable of evaluating parameters such as D1 cm3 or D2 cm3
that are routinely used in BT. Moreover, stereotactic radio-
therapy has proven to be of very good efﬁcacy in treating
inoperable relapses of gynecological malignancies,8 indicating
that comparison of stereotaxis and BT would be appropriate.
The present dosimetric study compares the treatment
plans of 3D image-guided brachytherapy and stereotactic
robotic radiotherapy with online image  guidance.
2.  Methods  and  materials
This study included ten patients with locally advanced inoper-
able cervical cancer, who  were treated with 3D MRI-based BT.
For each patient, two plans were made—one for BT and one
for stereotactic radiotherapy—and their dosimetric character-
istics were compared. Median volumes of GTV (gross tumor
volume), HR CTV and IR CTV (intermediate-risk clinical tumor
volume) were 2.7 cm3 (range 0.9–16.0 cm3), 33.1 cm3 (range
23.1–63.4 cm3) and 109.4 cm3 (range 77.0–189.0 cm3), respec-
tively.
2.1.  BT  treatment  planning
Our BT treatment technique using MRI  and CT data fusion
was described elsewhere.9 In brief, MRI  with brachytherapy
applicators in situ (intracavitary with no needle – 7 cases,
intracavitary plus one needle – 2 cases, intracavitary plus
two needles – 1 case) was performed on a 1.5 T system (Signa
Excite HD, GE Healthcare, Milwaukee, WI,  USA) using T2-
weighted axial, coronal, and sagittal fast spin echo sequences
(3 mm slice thickness, no gap). Target volumes and OAR
were contoured according to the Gynaecological GEC-ESTROiotherapy 1 9 ( 2 0 1 4 ) 399–404
Working Group recommendations. The treatment planning
system BrachyVision 8.6 (Varian, Palo Alto, CA) was used
for optimization based on EQD2 values, however physical
values were used for comparison with results of stereotactic
treatment planning system. The prescribed dose for HR CTV
D90 was 6× 5 Gy (six fractions in two weeks after ﬁnishing
external beam radiotherapy 45 Gy in 25 fractions). Dose
volume constraints for the different OAR were 70 Gy EQD2
as a maximum dose for the most exposed tissues of the
rectum (rectum D2 cm3) and sigmoid colon (sigmoid D2 cm3),
and 90 Gy EQD2 in 2 cm3 of the bladder (Bladder D2 cm3). No
volume constraints were applied for the vagina.
2.2.  Treatment  planning  of  stereotactic  radiotherapy
We used the CyberKnife (CK) system with a 6 MeV  linear accel-
erator. The treatment plans were non-isocentric (sequential
optimization) and non-coplanar with approximately 200 pen-
cil beams. Plans were designed to cover 100% of HR CTV with
the prescribed dose, the constraint for the homogeneity index
was higher than 2.0 and constraints for OAR were the same
as for BT optimization. For each patient, the CT images with
structures contoured for BT were transferred to the CK treat-
ment planning system (MultiPlan 3.5.2, Accuray, Sunnyvale,
CA). Because of the proven sub-millimeter precision of the CK
system,10,11 we omitted the set-up margin, such that planning
target volume (PTV) was equal to HR CTV. Since systematic
low-dose regions leading to local recurrence can be detected
even when HR CTV D90 is optimal,7 we used the dose that
covers 98% of the target volume (D98 HR CTV) as reference
and compared other parameters, including HR CTV D90, GTV
D100, D90, and intermediate risk (IR) CTV D100, D90, according
to the recommendation of GEC ESTRO.4 For different OARs, we
compared the typically recommended parameters: D0.1 cm3,
1 cm3, and 2 cm3. In addition, the HR CTV D60 and 30 were
compared, and an averaged DVH curve for both methods was
constructed. We  also compared the Dmean values obtained for
the scanned part of the body in order to evaluate differences
in the integral dose of radiation between plans.
2.3.  Statistics
For statistical analyses, GraphPad Prism 4 for Windows was
used (GraphPad Software Inc., San Diego, CA). All dosimetric
data were compared with a paired two-tailed Student’s t-test,
and statistical signiﬁcance was assumed at p < 0.05.
3.  Results
Of the ten studied cases, the dose from D100 GTV was com-
parable for both devices, on average, the BT GTV D90  was
10–20% higher than for CK, due to the dose inhomogeneity
of BT around the applicator (Table 1). On the other hand,
the HR CTV D90 was higher for CK in eight of ten cases,
with an average difference of 10–20% (Table 2). In low-dose
parameters, such as D60 or D30, the BT plans reached higher
doses by 25% and 45%, respectively (Table 2). Based on these
ﬁndings, we  developed typical DVH plans (the DVH curves
were created from average values of 10 patients.) for BT and
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Table 1 – Comparison of D100 and D90 GTV and IR CTV values for CyberKnife (CK) and brachytherapy (BT). Comparison
between IR CTV D90 and D100 values clearly shows steeper gradient outside the HR CTV for CK.
GTV IR CTV
D (Gy) D100 CK D100 BT D90 CK D90 BT D100 CK D100 BT D90 CK D90 BT
Average 7.8 7.7 8.9 9.8 0.6 1.7 2.8 2.7
Median 7.2 7.9 8.0 11.2 0.6 1.7 2.8 2.6
Min 5.5 4.3 7.1 5.4 0.4 0.9 2.1 2.3
Max 11.3 10.4 12.5 14.1 1.1 2.9 3.8 4.1
Table 2 – Comparison of D100, D90, D60 and D30 HR CTV values for CyberKnife (CK) and brachytherapy (BT). The values
in the second column are the same for CK and BT.
D (Gy) D98 CK + BT D100CK D100 BT D90 CK D90 BT D60 CK D60 BT D30 CK D30 BT
Average 5.1 4.4 4.6 7.3 6.1 8.5 11.5 9.4 17.9
Median 5.0 4.3 4.5 6.8 6.1 8.0 10.6 8.7 16.1
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tereotaxis, and a parameter D85 where the two curves
rossed and the doses were equal for both techniques was
ound (Fig. 1). Fifteen percent of HR CTV (the peripheral part)
eceived a higher dose from CK, while 85% of the target volume
eceived higher doses from BT, including 60% of the volume
ith a dose higher than 200% the prescribed dose (Fig. 2). IR
TV D90 was similar for both methods, while the D100 was
ower for CK (Table 1).
Regarding OAR, median D1 cm3, D2 cm3 values for BT
lans were 4.9 Gy (range 4.0–5.3), 4.6 Gy (range 3.8–4.8), 3.3 Gy
range 3.1–3.6), 3.0 Gy (range 2.8–3.3) and 3.5 Gy (range 2.6–4.0),
.2 Gy (range 2.4–3.6) for the bladder, rectum and sigmoid,
espectively. Fig. 3 and Table 3 demonstrate a signiﬁcant organ-
paring effect of CK compared to brachytherapy (20–30% lower
oses in 0.1 cm3, 1 cm3, and 2 cm3).
To estimate the probability of radiation-induced second
ancers, we  calculated the Dmean of the contoured body. The
ntegral dose was higher for BT than for CK (0.2 Gy and 0.1 Gy,
espectively), but CK create larger areas with lower doses
Fig. 2).
ig. 1 – Derived dose volume histogram (DVH) of HR CTV for Cyb
TV D100, D98, D90, D60 and D30 were  created from average val
uch higher dose for BT.5.1 6.8 7.8 7.6 11.8
7.2 11.8 15.8 13.2 27.0
4.  Discussion
The combination of brachytherapy and external beam radio-
therapy is considered to be the gold standard treatment for
advanced cervical cancer.1 Historically, the dosing parameters
for brachytherapy have used a system that speciﬁed the dose
to standardized points A and B as well as to rectal and blad-
der points. This system, based on 2D images, is still used in
the majority of current clinical practice.3 In recent years, more
sophisticated recommendations have been published that put
emphasis on using 3D image-guided brachytherapy to opti-
mize the dose coverage to the tumor while reducing the dose
to adjacent critical structures.4 Direct comparison of 2D and
3D brachytherapy appears to favor the 3D approach.5 In 3D
brachytherapy, precise deﬁnition of target volume is of utmost
importance. Our previously published data demonstrate the
feasibility and precision of MRI-based pre-planning,12 so this
approach was used as a reference for the comparison with CK
plans.
erKnife (CK) and brachytherapy (BT). The DVH curves for HR
ues of 10 patients. D30 values comparison clearly shows
402  reports of practical oncology and rad
Fig. 2 – Example of dose distributions (cGy) on axial views
for one fraction; CyberKnife-CK (top) and brachytherapy-BT
(bottom). Almost the same coverage of HR CTV (high risk
clinical target volume) by prescribed isodose line for both
methods. Irregular isodose lines, larger region of low dose
and rectum sparing dose distribution for CK compared to
BT.
Fig. 3 – (a–i) Comparison between CyberKnife (CK) and brachythe
sigmoid, each with (a, d, g) D0.1, (b, e, h) D1, and (c, f, i) D2.iotherapy 1 9 ( 2 0 1 4 ) 399–404
It was recently reported that the CK plan is comparable to
the 2D BT plan.13 The comparison of 3D BT and IMRT/IMPT
has also been previously published, showing clear superiority
of BT.14 To the best of our knowledge, this is the ﬁrst study to
compare CK stereotactic RT with 3D MRI-based brachytherapy.
Our results demonstrate that the conformality, homogene-
ity and target coverage of CK plans are higher to those of
3D brachytherapy, which is in agreement with the published
article.13 CK plans showed a very strong dose gradient with
lower values on D100 IR CTV, while CK was equal to BT at
D90. Moreover, stereotactic radiotherapy is noninvasive and
can easily be delivered, even to patients that cannot tolerate
anesthesia and to tumors for which brachytherapy cannot be
feasible.
Before we declare CK’s superiority to brachytherapy, sev-
eral very important questions must be answered. The ﬁrst of
them is the question of sufﬁcient image  guidance. The uterus
is a mobile structure that can move beyond 1 cm between
fractions15 depending on the ﬁlling status of the bladder and
rectum,16 so intrafraction movement  can be expected as well.
Candidates for CK virtual brachytherapy would certainly need
urethral catheter and an empty rectum in order to minimize
uterine moving. To ensure precise image  guidance, ﬁducials
must be placed in the cervix and vaginal vault or parametria.17
When target motion is tracked in real time using ﬁducial
marker, the same submillimeter dose delivery precision can be
achieved as in other localities 18 and no CTV-PTV is needed for
cervix carcinoma as reported previously.13 Moreover, overview
of some uncertainties related to 3D volumetric image  guided
BT has been published recently.19
There are also some dosimetric concerns. As mentioned
above, brachytherapy dose distribution is more  inhomoge-
neous to that of CK, with hot areas inside and around
the catheters. In principle, it is difﬁcult to compare two
rapy (BT) for (a, b, c) bladder, (d, e, f) rectum, and (g, h, i)
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Table 3 – Organ at risk (OAR) – comparison of D0.1 cm3, D1 cm3 and D2 cm3 values for CyberKnife (CK) and brachytherapy
(BT).
OAR Bladder CK Bladder BT Rectum CK Rectum BT Sigmoid CK Sigmoid BT
D (Gy) D0.1 D1 D2 D0.1 D1 D2 D0.1 D1 D2 D0.1 D1 D2 D0.1 D1 D2 D0.1 D1 D2
Average 4.1 3.6 3.3 5.8 4.8 4.4 2.3 1.9 1.8 3.9 3.3 3.0 2.6 2.3 2.0 4.1 3.5 3.2
Median 4.1 3.7 3.4 5.6 4.9 4.6 2.3 2.1 2.0 3.9 3.3 3.0 2.1 1.9 1.7 4.2 3.5 3.2
0.
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pproaches that differ completely in the most important dosi-
etric parameters. Because low-dose regions leading to local
ecurrence could be detected even when D90 is optimal,7
e  decided to make HR CTV D98 a benchmark and com-
are other standard dosimetric parameters. We  consider the
resent study as a starting point for an important discussion
bout the potential advantages and limitations of stereotactic
adiotherapy as a “virtual brachytherapy” method.
Even more  important are radiobiological considerations.
ith identical fractionation regimens, virtual brachytherapy
overed the HR CTV more  homogenously and with a higher
ose to peripheral parts, and had better organ-sparing effects.
owever, with BT the part of tumor around the catheter is
rradiated with a very high dose, much higher than with CK.
t could be possible to increase the prescribed dose in vir-
ual brachytherapy, because the dose to critical organs was
ow. However, the brachytherapy dose distribution cannot be
ntirely the same as in CK. Therefore, the most important
uestion is whether the overdosage of some parts of the tumor
s a factor that contributes to the excellent effectiveness of
rachytherapy. However, if there is some beneﬁt of partial
verdosage, then we  must acknowledge the effectiveness of
n ablative dose of radiation to a small part of the target vol-
me; in this case, we  need to ask whether it is even necessary
o irradiate homogeneously. Until now, this has been one of
he paradigms in radiation oncology according to ICRU recom-
endations; a properly designed set of clinical studies should
e performed to test whether it is correct. Signiﬁcant disad-
antage of CK session is the duration of each fraction being
onger than that of high dose rate, which can cause a loss in
ytotoxicity.
Some patients with advanced cervical cancers are not can-
idates for brachytherapy due to the problem of successful
arget coverage.20 Based on our ﬁndings, we  are conﬁdent that
irtual brachytherapy based on stereotactic radiotherapy is
 good option for these patients, as it is certainly less toxic
nd potentially more  efﬁcient than classical external beam
adiotherapy.
.  Conclusions
tereotactic radiotherapy with CK produces treatment plans
ith higher conformality and homogeneity to those produced
y 3D MRI-navigated brachytherapy in patients with advanced
ervical cancer. However, the higher homogeneity of CK allows
he irradiation of only 15% of the target volume (peripheral
arts) at a higher dose than BT, while the remaining 85% of
he TV (central parts) receive a much higher dose from BT7 3.5 3.1 2.8 1.0 0.9 0.8 3.0 2.6 2.4
4 4.4 3.6 3.3 4.6 4.0 3.7 5.1 4.0 3.6
than from CK. While BT remains to be the best method for
dose escalation due to the signiﬁcant organ-sparing effect
of CK, patients that are not candidates for BT could beneﬁt
from stereotactic robotic radiotherapy more  than from classi-
cal external beam radiotherapy.
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